Frontier Pharma

Innovative
Licensing
Opportunities in
Non-Hodgkin
Lymphoma
2015
No. Pages : 115
Published on : August - 2015

Report Overview
About Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021
Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most
common cause of cancer-related mortality. Such a poor outlook, particularly for patients with
advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is
undergoing a gradual change from a focus on generic chemotherapy regimens to complex treatment
landscape based on different NSCLC subtypes and the presence of various molecular aberrations. In
the current market, patients with non-squamous histology can be treated with more efficacious
therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK
can be prescribed targeted therapy. While the NSCLC developmental pipeline must aim to improve the
outlook for all patients, there is currently a lack of options for patients with squamous cell histology or
other detectable molecular characteristics besides EFGR and ALK mutations.
Get Full Details On : http://www.researchbeam.com/non-small-cell-lung-cancer-therapeutics-inmajor-developed-to-2021-emergence-of-immunotherapies-drives-growth-and-creates-acompetitive-second-line-market

Report Overview
Scope
The NSCLC market will be valued at $10.9 billion in 2021, growing from $6.1 billion in 2014 at a CAGR
of 8.5% - How will immunotherapies such as Keytruda affect growth?
- What effect will patent expirations of Tarceva and Alimta have on market value?
The NSCLC pipeline is large and diverse, with an increased presence of mAbs and specific targeted
therapies in contrast to the market - What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
- What implications will the increased focus on targeted therapies have on the future of NSCLC
treatment?
Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the
market over the forecast period -

Report Overview
- How have promising late-stage therapies performed in clinical trials?
- How would the approval of Rociletinib affect the competitive landscape?

- What is the individual commercial forecast for each therapy?

The market forecasts indicate that the US contributes the most to global market value due to a large
treatment population and the high price of premium therapies.
- How will ACoT and market size vary between the eight major markets?

- How could a change in risk factors such as population age or smoking habits influence the market?
Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging
from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?

- What were the terms and conditions of key licensing deals?

Reasons to buy
This report will allow you to - Understand the current clinical and commercial landscape by considering disease pathogenesis,

Report Overview
diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical
comparison of marketed therapies.
-

Visualize the composition of the NSCLC market in terms of dominant therapies for each patient
subset along with their clinical and commercial standing. Unmet needs in the current market are
highlighted to allow a competitive understanding of gaps in the current market.

- Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type
and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter
the market over the forecast, highlighting clinical performance, potential commercial positioning, and

how they will compete with other therapies.

- Predict NSCLC market growth in eight major markets with epidemiological and ACoT forecasts across
the US, Canada, UK, France, Germany, Italy, Spain and Japan, as well as individual drug contributions to
market growth.

- Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and
co-development deals.

Table Of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Disease Introduction 8
2.2 Epidemiology 9
2.3 Etiology and Pathophysiology 9
2.3.1 Adenocarcinoma 11
2.3.2 Squamous Cell Carcinoma 13
2.3.3 Large Cell Carcinoma 15
2.3.4 Immunotherapy 16
2.4 Symptoms 17
2.5 Diagnosis 17
2.6 Prognosis 19

Table Of Contents
2.7 Treatment 20
2.7.1 Treatment Algorithm 21
2.7.2 First-Line Treatment 21
2.7.3 Maintenance Therapy 23

2.7.4 Second-Line Treatment 24

2.7.5 Third-Line Therapy 25
2.7.6 Adjuvant Therapy 25
2.8 Marketed Product Heatmaps 25

3 Marketed Products 29
3.1 Overview 29
3.2 Chemotherapies 29
3.3 Alimta - Eli Lilly 29

3.4 Abraxane - Celgene Corporation 30

3.5 Tarceva - Roche 31

Table Of Contents
3.6 Iressa - AstraZeneca 32
3.7 Gilotrif - Boehringer Ingelheim 33
3.8 Xalkori - Pfizer 34
3.9 Avastin - Roche 34

3.10 Cyramza - Eli Lilly 35

3.11 Opdivo - Bristol-Myers Squibb 36
3.12 Zykadia - Novartis 37
3.13 Alectinib - Roche 38

3.14 Conclusion 39

Enquiry about this report @ http://www.researchbeam.com/non-small-cell-lung-cancertherapeutics-in-major-developed-to-2021-emergence-of-immunotherapies-drives-growth-and-

creates-a-competitive-second-line-market/enquire-about-report

FOR MORE DETAILS

Visit us at :

http://www.researchbeam.com/non-small-cell-lung-cancertherapeutics-in-major-developed-to-2021-emergence-ofimmunotherapies-drives-growth-and-creates-a-competitivesecond-line-market
Stay With Us:

TELEPHONE: +1 (800) 910-6452

E-MAIL: sales@researchbeam.com

5933 NE Win Sivers Drive,

#205, Portland, OR 97220
United States